title: Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH.
authors.affiliation: University Children's Hospital Cologne, Cologne, Germany; University of Cologne, Cologne, Germany. Electronic address: sandra.habbig@uk-koeln.de.
authors.forename: Sandra
authors.initials: S
authors.lastname: Habbig
authors.affiliation: Bioscientia Center for Human Genetics, Ingelheim, Germany; University Freiburg Medical Center, Freiburg, Germany.
authors.forename: Carsten
authors.initials: C
authors.lastname: Bergmann
authors.affiliation: University Children's Hospital Cologne, Cologne, Germany.
authors.forename: Lutz T
authors.initials: LT
authors.lastname: Weber
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D065766:Atypical Hemolytic Uremic Syndrome / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology; D017242:Complement Factor H / Q000235:genetics*; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D009154:Mutation; D010597:Pharmacogenetics / Q000379:methods; D057285:Precision Medicine; D055502:Secondary Prevention; D028761:Withholding Treatment
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D017242:Complement Factor H; C481642:eculizumab